Longitudinal echocardiographic and clinical follow-up of patients undergoing mitral valve surgery without concomitant tricuspid valve repair

Netherlands Heart Journal, Oct 2018

Background In patients with mild to moderate functional tricuspid regurgitation (TR) and absence of right ventricular dysfunction or tricuspid annulus (TA) dilatation, there is currently no indication for concomitant tricuspid valve (TV) repair during elective mitral valve (MV) surgery. However, long-term results are conflicting. Here, we sought to determine the clinical outcome of this cohort, the rate of TR progression after MV surgery and the role of MV aetiology. Methods Patients for elective MV surgery without concomitant TV repair were retrospectively analysed with longitudinal echocardiographic and clinical follow-up, focusing on TR progression and MV aetiology. Linear regression analysis was performed for change in TR at follow-up, using pre-determined variables and confounders. Results In total 204 patients without TV repair were analysed. Development of more than moderate TR after a median of 3.1 [1.6–4.6] years was rarely seen: only in 2 out of 161 patients (1.2%) with known TR grade at follow-up. Overall, median preoperative and late postoperative TR grade were equal (p = 0.116). Subanalysis showed no significant difference in MV aetiology subgroups. Preoperative TR grade and male gender were inversely correlated to change in TR. Mortality was not influenced by the 1‑year postoperative TR severity. Conclusion Our data showed that in a study population of patients with mild to moderate TR undergoing MV surgery without concomitant TV repair, significant late TR was rarely seen. Based on our study, it is safe to waive concomitant TV repair in this specific patient cohort.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1007%2Fs12471-018-1159-4.pdf

Longitudinal echocardiographic and clinical follow-up of patients undergoing mitral valve surgery without concomitant tricuspid valve repair

Netherlands Heart Journal pp 1–10 | Cite as Longitudinal echocardiographic and clinical follow-up of patients undergoing mitral valve surgery without concomitant tricuspid valve repair AuthorsAuthors and affiliations R. JansenB. R. van KlarenboschM. J. CramerR. C. A. MeijerP. H. M. WestendorpH. W. J. MeijburgJ. J. J. BucxS. A. J. ChamuleauJ. Kluin Open Access Original Article First Online: 01 October 2018 86 Downloads Abstract Background In patients with mild to moderate functional tricuspid regurgitation (TR) and absence of right ventricular dysfunction or tricuspid annulus (TA) dilatation, there is currently no indication for concomitant tricuspid valve (TV) repair during elective mitral valve (MV) surgery. However, long-term results are conflicting. Here, we sought to determine the clinical outcome of this cohort, the rate of TR progression after MV surgery and the role of MV aetiology. Methods Patients for elective MV surgery without concomitant TV repair were retrospectively analysed with longitudinal echocardiographic and clinical follow-up, focusing on TR progression and MV aetiology. Linear regression analysis was performed for change in TR at follow-up, using pre-determined variables and confounders. Results In total 204 patients without TV repair were analysed. Development of more than moderate TR after a median of 3.1 [1.6–4.6] years was rarely seen: only in 2 out of 161 patients (1.2%) with known TR grade at follow-up. Overall, median preoperative and late postoperative TR grade were equal (p = 0.116). Subanalysis showed no significant difference in MV aetiology subgroups. Preoperative TR grade and male gender were inversely correlated to change in TR. Mortality was not influenced by the 1‑year postoperative TR severity. Conclusion Our data showed that in a study population of patients with mild to moderate TR undergoing MV surgery without concomitant TV repair, significant late TR was rarely seen. Based on our study, it is safe to waive concomitant TV repair in this specific patient cohort. KeywordsTricuspid valve repair Functional tricuspid regurgitation Mitral valve surgery Mitral valve aetiology  The Authors R. Jansen and B.R. van Klarenbosch contributed equally to the manuscript. Electronic supplementary material The online version of this article ( https://doi.org/10.1007/s12471-018-1159-4) contains supplementary material, which is available to authorized users. What’s new Guidelines recommend concomitant tricuspid valve (TV) repair for severe tricuspid regurgitation (TR); however, less is known regarding the management of mild to moderate TR. Our study showed that in patients with moderate TR or less, undergoing mitral valve (MV) surgery without concomitant TV repair, significant late functional TR was seldom seen, and change in TR severity was not influenced by the MV aetiology. Clinical decision-making regarding concomitant TV repair during MV surgery can be safely based on the preoperative evaluation of TR grade: it is safe to waive concomitant TV repair in our specific patient cohort. Introduction Mitral valve (MV) disease represents an increasing health burden, due to ageing and population growth [1]. Approximately 30–50% of patients with severe mitral regurgitation (MR) have significant tricuspid regurgitation (TR) [2]. Functional TR carries an adverse prognosis which is related to its severity [3]. It was historically believed that TR may improve after correction of the MV pathology [4]. However, recent data have shown an increase in TR in a still unclassified subgroup, irrespective of residual or recurrence of MV disease or preoperative TR [5, 6, 7, 8]. Reoperation may be associated with high mortality [9]. Therefore, guidelines recommend concomitant tricuspid valve (TV) repair for severe TR (class I), as it improves mortality and morbidity in these patients [10, 11, 12]. However, less is known regarding the management of mild to moderate TR. Recent guidelines recommend concomitant tricuspid annuloplasty for a tricuspid annulus (TA) diameter of ≥40 mm or >21 mm/m2 (class IIa) regardless of the TR severity, solely based on expert opinion [10, 11, 13, 14, 15]. While concomitant TV repair has proven to be a safe procedure [14, 16, 17, 18], it seems severely underutilised in daily practice [12, 18, 19, 20]. Insight into the longitudinal echocardiographic and clinical follow-up, including identification of risk factors for TR progression, is of importance to evaluate and complement current guidelines. The purpose of this study was to evaluate the echocardiographic and clinical results in patients with moderate TR or less, undergoing MV surgery without concomitant TV repair, in order to: (1) analyse postoperative TR progression and clinical outcome, and (2) evaluate the role of MV aetiology as potential risk factor for postoperative TR progression. Methods Study population Between 2006 and 2014 a total of 1,226 patients underwent MV surgery in the University Medical Center Utrecht (UMCU), the Netherlands (Fig. 1). We analysed the two-dimensional (2D) transthoracic echocardiograms (TTE) and clinical data of 204 patients meeting the inclusion criteria: (1) age ≥18 years; (2) preoperative TR grade <3; (3) referred for elective MV surgery with or without coronary artery bypass grafting and no concomitant TV repair or other concomitant procedures (e. g. MAZE or aortic valve surgery); and (4) follow-up in a participating centre. Our study was approved by the institutional review board of the UMCU, which waived patient consent. Open image in new window Fig. 1 Study flowchart (MV mitral valve, UMC University Medical Center, TV tricuspid valve, CABG coronary artery bypass grafting, TR tricuspid regurgitation, TTE transthoracic echocardiography, * excluding concomitant TV repair) Data collection Preoperative and perioperative information was retrieved from the surgical database of the UMCU. Postoperative follow-up data and echocardiographic images and/or reports were obtained from the treating physician. Re-evaluation of the images was performed off-line using Xcelera software (Philips Healthcare, the Netherlands). The routine evaluation of echocardiograms was performed by experienced sonographers. Echocardiographic measurements were obtained in accordance with the guidelines [21, 22]. Left ventricular (LV) and right ventricular (RV) function, and atrial and ventricular dimensions were qualified and, if possible, quantified. The severity of valvular disease was graded 0–4 (including grade 0.5 for trace severity) by a cardiologist of the participating centre with a special interest in cardiac imaging, using an integrative approach based on the echocardiographic criteria as recommended by the European guidelines [10, 21]. For data analysis TR grade was divided into four groups: none, trace or mild, moderate, and more than moderate TR. Additionally the change in TR grade between the preoperative and most recent TTE was determined. In case of insufficient data regarding TR grade and TA dimensions, the images were re-evaluated in the apical 4‑chamber view. TA was considered dilated when ≥40 mm [21]. Each patient was allocated to either the organic or functional MV subgroup: organic when a specific component of the MV apparatus was diseased, or functional when caused by secondary changes induced by abnormal ventricular size and leaflet retraction. Statistical analysis Statistical analysis was done using SPSS (version 21.0, IBM Corporation, New York). Continuous variables were expressed as mean (±SD) and compared using Student’s t‑test in case of normally distributed data, or expressed as median (interquartile range) and compared using Wilcoxon signed-rank test or Mann-Whitney U test for non-normal distribution. One-way ANOVA or Kruskal-Wallis was used to compare >2 unpaired groups. Categorical data were described using frequencies and percentages. We performed comparative evaluations via the χ2 or McNemar’s test for binary results, and χ2 or Wilcoxon signed-rank test in case of ordinal data. The Kaplan-Meier method was used to calculate long-term survival for the different grades of 1‑year postoperative TR. Statistical significances between the survival curves was determined by a log-rank test; the p-value <0.05 was considered statistically significant. Ordinal regression analysis for change in TR grade (between preoperative and most recent TTE) was performed based on complete case analysis, including univariable and multivariable ordinal regression on pre-determined variables of interest at baseline (MR grade, MV aetiology, MV aetiology subcategories, TR grade, TA diameter, RV function, RA dilatation, LV function, LA dilatation and gender) and potential confounders (age, NYHA class, pacemaker implantation and atrial fibrillation). Results Patient characteristics Baseline characteristics are shown in Table 1. In Online Resource 1 (Supplementary material) the subcategories per MV aetiology are depicted. Patients with functional MV disease (30.4%) were significantly older compared with the organic subgroup (69.6%). Also NYHA class, EuroSCORE and rates of the comorbidities hypertension, chronic obstructive pulmonary disease, known coronary artery disease, diabetes, and renal failure were significantly higher in the functional aetiology subgroup, particularly for ischaemic MR. Preoperative MV annulus dilation was present in 58.5% of patients with organic and >90% of patients with functional valve disease. Clinically important mitral stenosis (MS) was only seen in the organic subgroup (9.9%). MV repair was more often performed in patients with functional disease (96.8%), compared with 18.3% MV replacement in the organic aetiology subgroup (mainly for rheumatic disease or severe calcifications). Patients with more preoperative TR showed a higher NYHA class (p = 0.011). Regarding the surgical characteristics, more MV replacements were performed in patients with moderate TR at baseline compared with lower grades (p = 0.017). Standard median sternotomy was performed in 98.5%. Three patients underwent a right anterior thoracotomy. Access to the MV was achieved through a left atriotomy. Table 1 Baseline characteristics and procedure details (n = 204) Patient Characteristics Age (years)  61.1 ± 13.1 Male gender 125 (61.3) BSA (m2)   2.2 ± 0.2 NYHA class ≥III  92 (45.1) EuroSCORE II   1.4 [0.8–3.5] Hypertension  63 (30.9) Known coronary artery disease (n = 203)  84 (40.9) Diabetes  23 (11.3) COPD  18 (8.8) Renal failure  38 (18.6) Atrial fibrillation  38 (18.6) Pacemaker or ICD   8 (3.9) Surgical Characteristics Organic MV disease 142 (69.6) – Myxomatous degeneration  79 (38.7) – Fibroelastic degeneration  47 (23.0) – Rheumatic disease  13 (6.4) – Other   3 (1.5) Functional MV disease  62 (30.4) – Ischaemic cardiomyopathy  46 (22.5) – Other  16 (7.8) Preoperative MR (n = 203)   >Moderate 164 (80.2) Preoperative TR   – No  29 (14.2) – Trace or mild 126 (61.8) – Moderate  49 (24.0) >Moderate   0 (0.0) Preoperative TA ≥ 40 mm (n = 165)  14 (8.5) Preoperative TA diameter (mm) (n = 165)  33 ± 4 MV replacement  28 (13.7) – Mechanical  17 (8.3) – Bioprosthesis  11 (5.4) MV repair 176 (86.3) – Physio ring 137 (67.2) – Cosgrove band  38 (18.6) Elevated RVSP (n = 118)  51 (43.2) Concomitant CABG  75 (36.8) Cross-clamp time (minutes) 118 [92–149] Data are depicted as n (%), mean ± SD or median [interquartile range] BSA body surface area, NYHA New York Heart Association, COPD chronic obstructive pulmonary disease, ICD implantable cardioverter-defibrillator, MV mitral valve, MR mitral regurgitation, TR tricuspid regurgitation, TA tricuspid annulus, RVSP right ventricular systolic pressure, CABG coronary artery bypass crafting Clinical results Clinical outcomes are depicted in Table 2. Of the 204 patients, 5 (2.5%) died within 30 days (shock n = 3, respiratory failure n = 1, acute neoplastic disease n = 1). All had ischaemic MR. Reoperation <30 days after surgery occurred in 9.3%, mainly for bleeding complications (7.8%). Of the patients with postoperative AF, this rhythm was already present at baseline in 29.8%. The prevalence of AF at follow-up was similar to baseline, whereas the NYHA class ≥III significantly decreased. The overall survival after a median follow-up of 5.5 [3.7–8.1] years was 87.3%, and significantly better for the organic compared with functional MV aetiology (92.3% versus 75.8%). The highest mortality rate was seen for ischaemic MR (28.3%). There was no significant difference in survival according to TR grade at 1 year (Fig. 2, p = 0.972). In 50% of the deceased patients TR was never severe and therefore not a cause of mortality; the TR grade was unknown in the remaining subjects. Table 2 Clinical results at follow-up and echocardiographic characteristic at most recent follow-up Clinical Characteristics Early outcome   Operative mortality   0 (0.0) 30 days mortality   5 (2.5) New permanent pacemaker or ICD   5 (2.5) Atrial fibrillation 104 (51) Reoperation  19 (9.3) – due to bleeding  16 (7.8) – other   3 (1.5) Late outcome   Postoperative (for most recent FU analysis) (years)   3.4 [1.8–5.2] Postoperative (for survival analysis) (years)   5.5 [3.7–8.1] Mortality  26 (12.7) – Cardiovascular  20 (9.8) – Other   6 (2.9) NYHA class ≥III (n = 184)  12 (6.5) New reoperation (n = 184)   7 (3.8) – Due to mitral stenosis post MV surgery   1 (0.5) – Due to endocarditis   2 (1.0) – Due to bleeding   1 (0.5) Rehospitalisation (n = 187)  66 (35.3) – Cardiovascular  46 (22.5) Congestive heart failure (n = 183)  19 (10.4) New permanent pacemaker or ICD (n = 185)  14 (7.6) Atrial fibrillation (n = 183)  38 (20.8) OAC (n = 180)  78 (43.3) Stroke (n = 191)   2 (1.0) Echocardiographic Characteristics Time after surgery, years (n = 164)   3.1 [1.6–4.6] LV function, n (%) (n = 160)   – Poor (EF < 30%) or moderate (EF 30–44%)  33 (20.6) LV EF, % ± SD (n = 103)  55 ± 15 LA dilatation, n (%) (n = 135)   – Moderate or severe  34 (25.2) RA dilatation, n (%) (n = 155)   – Moderate or severe  11 (7.1) RV function, n (%) (n = 147)   – Poor or moderate  11 (7.5) TAPSE, cm ± SD (n = 129)   1.8 ± 0.5 MR grade, n (%) (n = 159)   >Moderate   3 (1.9) TR grade, n (%) (n = 161)   – No  24 (14.9) – Trace or mild 107 (66.5) – Moderate  28 (17.4) >Moderate   2 (1.2) TA ≥ 40 mm, n (%) (n = 154)  23 (14.9) – Of whom had pre-operative TA ≥ 40 mm   3 (13.0) Elevated RVSP, n (%) (n = 97)  14 (14.4) Data are depicted as n (%), mean ± SD or median [interquartile range] ICD implantable cardioverter-defibrillator, NYHA New York Heart Association, MR mitral regurgitation, OAC oral anticoagulation, LV left ventricular, EF ejection fraction, LA left atrial, RA right atrial, TAPSE tricuspid annular plane systolic excursion, TR tricuspid regurgitation, TA tricuspid annulus, RVSP right ventricular systolic pressure. Open image in new window Fig. 2 Kaplan-Meier to illustrate survival according to grade of tricuspid regurgitation at 1 year postoperatively (p = 0.972). Number at risk and number of events are depicted Echocardiographic results Overall echocardiographic results at follow-up are shown in Table 2. In 204 patients echocardiographic data were available at baseline. Postoperatively, the TTE was available in 202 patients (2 subjects passed away), while TR grade could be determined in 161 patients using the echocardiographic data or images (78.9%). Fig. 3 shows the overall change, including median changes per baseline TR grade subgroups. In general, almost all patients with no TR at baseline developed some TR at late follow-up, whereas in subjects with preoperatively moderate TR an increase was never seen. Overall change in TR severity was limited and not significant: in only 3 out of 161 patients (1.9%) was a change in TR severity of >1 grade seen, whereas TR severity did not change in 86 patients (53.4%). RV systolic function as measured by tricuspid annular plane systolic excursion (TAPSE) decreased from 2.4 ± 0.5 cm preoperatively to 1.8 ± 0.5 cm (p < 0.001) at late follow-up. Medians of TR grade were similar amongst the MV aetiology groups (Table 3). Long-term follow-up showed 2 patients with TR grade ≥3 (Fig. 4); one in each of the MV aetiology subgroups. Median changes in TR grade were never significant over time in either the MV aetiology subgroup or the MV aetiology subcategories (Fig. 4). Baseline MR severity was significantly lower in the functional compared with the organic group (median 3.0 versus 4.0 respectively). Both preoperative and postoperative LV and RV function were poorer in functional MV disease. Table 3 Echocardiographic results in patients with organic and functional mitral valve disease   Organic (n = 142) Functional (n = 62) P-value Baseline LV function (n = 141/61)     – Poor (EF < 30%) or moderate (EF 30–44%)   4 (2.8) 25 (41.0) <0.0001 LA dilatation (n = 131/55)     – Moderate or severe  75 (57.3) 27 (49.1)  0.060 RA dilatation (n = 132/54)     – Moderate or severe  14 (10.6)  6 (11.1)  0.940 RV function (n = 127/55)     – Poor or moderate   1 (0.8)  3 (5.5)  0.003 TAPSE (cm) (n = 87/43)   2.3 [2.1–2.8]  2.0 [1.8–2.5]  0.001 MR grade (n = 141/62)     >Moderate 122 (86.5) 42 (67.7) <0.0001 TR grade (n = 142/62)     0.892 – No  21 (14.8)  8 (12.9)   – Trace or mild  88 (62.0) 38 (61.3)   – Moderate  33 (23.2) 16 (25.8)   >Moderate   0 (0.0)  0 (0.0)   TA ≥ 40 mm (n = 115/50)   8 (7.0)  6 (12.0)  0.285 TA diameter (mm) (n = 115/50)  33 ± 4 33 ± 5  0.994 MOST RECENT FOLLOW-UP LV function (n = 114/46)     – Poor (EF < 30%) or moderate (EF 30–44%)  10 (8.3) 23 (50.0) <0.0001 LA dilatation (n = 94/41)     – Moderate or severe  23 (24.5) 11 (26.8)  0.181 RA dilatation (n = 109/46)     – moderate or severe   7 (6.4)  4 (8.7)  0.596 RV function (n = 105/42)     – Poor or moderate   3 (2.9)  8 (19.0)  0.002 TAPSE (cm) (n = 90/39)   1.9 [1.6–2.1]  1.6 [1.4–2.1]  0.021 MR grade (n = 114/45)     >Moderate   2 (1.8)  1 (2.2)  0.218 TR grade (n = 115/46)     0.754 – No  16 (13.9)  8 (17.4)   – Trace or mild  79 (68. 8) 28 (60.9)   – Moderate  19 (16.5)  9 (19.6)   >Moderate   1 (0.9)  1 (2.2)   TA ≥ 40 mm (n = 111/43)  18 (16.2)  5 (11.6)  0.617 TA diameter (mm) (n = 110/43)  34 ± 5 34 ± 5  0.869 Change in TR grade (n = 115/46)     0.569 −2   4 (3.5)  2 (4.3)   −1  23 (20.0) 14 (30.4)   0  66 (57.4) 20 (43.5)   1  20 (17.4)  9 (19.6)   2   2 (1.7)  1 (2.2)   Data are depicted as n (%), mean ± SD or median [interquartile range] EF ejection fraction, LV left ventricular, LA left atrial, RA right atrial, RV right ventricular, TAPSE tricuspid annular plane systolic excursion, MR mitral regurgitation, TR tricuspid regurgitation, TA tricuspid annulus, RVSP right ventricular systolic pressure. Open image in new window Fig. 3 Grade of tricuspid regurgitation (a), and change in severity per grade at baseline (b) in patients with known tricuspid regurgitation severity at both baseline and most recent follow-up echocardiogram (n = 161, TR tricuspid regurgitation). a Median (IQR) tricuspid regurgitation grade at baseline: 1.0 (1.0–2.0), and most recent follow-up: 1.0 (1.0–1.0), p = 0.166. b Median (IQR) change in patients with no tricuspid regurgitation at baseline: 1.0 (1.0–1.0), mild or trace tricuspid regurgitation at baseline: 0.0 (0.0–0.0), and moderate tricuspid regurgitation at baseline: −1.0 (−1.0– −1.0), p < 0.0001 Open image in new window Fig. 4 Change in grade of tricuspid regurgitation per mitral valve aetiology subcategory (Median (IQR) change in myxomatous degeneration: 0.0 (−0.8–0.0), fibroelastic degeneration: 0.0 (0.0–0.0), rheumatic disease: 0.0 (−1.0–0.0), organic other cause: 0.0 (−1.0–NA), functional ischaemic cardiomyopathy: 0.0 (−1.0–1.0), functional other cause: 0.0 (−0.3–0.0), p = 0.575) Regression analysis Univariable regression analysis (Online Resource 2, supplementary material) showed a significant, negative correlation between change in TR grade and TR severity, TA diameter at baseline, and LA dilatation (regression coefficient (r) = −2.774, p < 0.0001, r = −0.839, p = 0.021, and r = −0.276, p = 0.024 respectively). In a multivariable regression model correcting for other parameters and confounders, only baseline TR grade and male gender remained independently correlated (r = −2.908, p < 0.0001 and r = −0.710, p = 0.027 respectively), suggesting more improvement of TR in patients with higher TR grade preoperatively, and more improvement in males compared with females. Discussion Our study of patients with moderate TR or less, undergoing MV surgery without concomitant TV repair, revealed three important findings. First, more than moderate late functional TR was seldom seen in this cohort at a median follow-up of 3.1 years. Secondly, overall change in TR severity was not significant when comparing the preoperative and late postoperative TR grade. Lastly, change in TR severity was not influenced by MV aetiology. Therefore our data suggest that clinical decision-making regarding concomitant TV repair during MV surgery in patients with moderate TR or less, can be safely based on the preoperative evaluation of TR grade. Prevalence and change of TR Several factors contribute to TR in MV disease. First, an increase in LA pressure may result in pulmonary hypertension and subsequent RV enlargement, remodelling and dysfunction. Consequently, the TA diameter increases, leading to leaflet tethering and/or papillary muscle displacement [23]. Second, MV disease may induce AF resulting in TR. Lastly, the TV may be affected by the same disease process as the MV aetiology leading to MR. In our study, only 2 (1.2%) patients developed more than moderate TR, in contrast with previous data showing a late significant TR prevalence ranging from 8–74% [6, 8, 14, 24, 25, 26]. A possible explanation for the non-significant change and therefore low prevalence of TR grade ≥3 in our cohort is the frequent performance of concomitant TV repair in patients with a TA annulus ≥40 mm. A proactive acquittal of the guidelines may have led to a selection bias, including less subjects with a larger TA diameter. Indeed, a brief evaluation of the TA diameter in patients: (1) without concomitant TV repair and TR grade <3 (current study cohort), (2) with concomitant TV repair and TR grade <3, and (3) with concomitant TV repair and TR grade ≥3, revealed a mean of 33 ± 4 mm, 42 ± 4 mm and 46 ± 6 mm respectively. Still, in 14 of the 165 patients with an available TA diameter (8.5%), the annulus at baseline was dilated, of whom 3 also showed a dilated TA at follow-up. Additionally, differences may depend on heterogeneity in study populations and outcome definitions. Also the follow-up period to determine significant TR remains controversial. Goldstone et al. showed that late postoperative TR is a slow progressive disease, with a marked increase (grade ≥3) after 9 years [8]. Our shorter follow-up period may therefore have led to a premature non-significant change in TR, possibly reflected by the decrease in RV systolic function (based on TAPSE) in our study population. However, other studies revealed a prevalence of significant TR (grade >2) in 48.6% and 18.2% after just 2 years [27, 28]. Lastly, our data do confirm guideline recommendations to defer concomitant TV repair in patients with non-severe TR: moderate TR at baseline decreased (69%) or remained unchanged (31%) in all subjects, and therefore TR never worsened. Although previous studies confirm these results [29], others have revealed TR grade >2 as being a risk factor for TR progression [7], possibly resulting from structural remodelling of, for example, RV and TA in patients with cardiomyopathy-related MV disease [30]. However, we expect less influence of structural remodelling on TR progression in our patient cohort, while 69.6% suffered from organic MV disease. In line with the idea of TR grade >2 being a risk factor, Chikwe et al. showed a higher 7‑year freedom from moderate or worse TR after concomitant TV repair compared with solely MV surgery in patients with moderate severity at baseline. On the contrary, the risk of developing moderate TR in subjects with no or mild regurgitation at baseline was low (17% versus 15%), matching our data. Nevertheless, their follow-up period was long (7 versus 3.1 years) [26]. Remarkably, our data more frequently showed a progression of TR in patients with lower baseline TR grade (probably explained by the regression toward the mean phenomenon), and female subjects [24, 29], although this was seldom significant TR and did not lead to excess mortality. MV aetiology as a potential risk factor Several studies have reported a high prevalence of postoperative TR in rheumatic MV [20, 24] and functional MR, with rheumatic MR being reported as an independent risk factor for late significant TR [20, 24, 25, 27, 31]. Our study showed TR progression towards more than moderate in only 2 patients (1.2%). There was no significant correlation between increased TR grade and MV aetiology, but this subanalysis was not very powerful. Differences at baseline and follow-up between the MV aetiology subgroups (e. g. lower survival and worse LV and RV function) can be explained by the poorer outcome in patients with ischaemic cardiac disease. Study limitations This study was retrospective with its inherent limitations. Only 17% of the 1,226 patients undergoing MV surgery in the UMC Utrecht were included. Main reasons are the exclusion of patients with follow-up in non-participating centres (682), and exclusion of patients with concomitant surgery (284). In addition, evaluation of 2D TTE in daily practice is limited by a poor imaging window, and especially TR-related measurements could not always be adequately obtained, further reducing the number of patients for clinical and echocardiographic data analysis towards 204, and for paired echocardiographic evaluation towards 161 subjects. Also standardised TR grading could not be carried out. Moreover, the surgical procedures performed in a single academic centre may not be applicable to other centres. Due to a low prevalence of late TR grade ≥3 postoperatively, no analyses for this endpoint could be performed, and no risk factors for significant postoperative TR were defined. A prospective study with longer follow-up is recommended to confirm our results. Conclusion In patients with mild to moderate TR who underwent elective MV surgery without concomitant TV repair, our study showed that significant late functional TR was seldom seen. Change in TR severity in the late postoperative period was not influenced by the MV aetiology, and mortality was not correlated to 1‑year postoperative TR severity. According to our study, it is safe to waive concomitant TV repair in this specific patient cohort, which is relevant for clinical decision-making in the heart team. Supplementary material 12471_2018_1159_MOESM1_ESM.docx (141 kb) Online Resource 1: Subcategories for the types of mitral valve etiology (figure). Online Resource 2 reflects the univariable and multivariable analysis in change in tricuspid regurgitation grade (n = 161) between baseline and most recent echocardiographic follow-up, and pre-determined variables of interest at baseline (table) References 1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005–11.CrossRefGoogle Scholar 2. Cohen SR, Sell JE, McIntosh CL, Clark RE. Tricuspid regurgitation in patients with acquired, chronic, pure mitral regurgitation. I. Prevalence, diagnosis, and comparison of preoperative clinical and hemodynamic features in patients with and without tricuspid regurgitation. J Thorac Cardiovasc Surg. 1987;94:481–7.PubMedGoogle Scholar 3. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43:405–9.CrossRefGoogle Scholar 4. Braunwald NS, Ross J Jr., Morrow AG. Conservative management of tricuspid regurgitation in patients undergoing mitral valve replacement. Circulation. 1967;35:I63–I9.CrossRefGoogle Scholar 5. Ariyoshi T, Hashizume K, Taniguchi S, et al. Which type of secondary tricuspid regurgitation accompanying mitral valve disease should be surgically treated? Ann Thorac Cardiovasc Surg. 2013;19:428–34.CrossRefGoogle Scholar 6. De Bonis M, Lapenna E, Pozzoli A, et al. Mitral valve repair without repair of moderate tricuspid regurgitation. Ann Thorac Surg. 2015;100:2206–12.CrossRefGoogle Scholar 7. Kwak JJ, Kim YJ, Kim MK, et al. Development of tricuspid regurgitation late after left-sided valve surgery: a single-center experience with long-term echocardiographic examinations. Am Heart J. 2008;155:732–7.CrossRefGoogle Scholar 8. Goldstone AB, Howard JL, Cohen JE, et al. Natural history of coexistent tricuspid regurgitation in patients with degenerative mitral valve disease: implications for future guidelines. J Thorac Cardiovasc Surg. 2014;148:2802–9.CrossRefGoogle Scholar 9. Xiao XJ, Huang HL, Zhang JF, et al. Surgical treatment of late tricuspid regurgitation after left cardiac valve replacement. Heart Lung Circ. 2004;13:65–9.CrossRefGoogle Scholar 10. Baumgartner H, Falk V, Bax JJ, et al. ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.CrossRefGoogle Scholar 11. Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2014;148:e1–e132.CrossRefGoogle Scholar 12. Desai RR, Vargas Abello LM, Klein AL, et al. Tricuspid regurgitation and right ventricular function after mitral valve surgery with or without concomitant tricuspid valve procedure. J Thorac Cardiovasc Surg. 2013;146:1126–32.CrossRefGoogle Scholar 13. Dreyfus J, Durand-Viel G, Raffoul R, et al. Comparison of 2‑dimensional, 3‑dimensional, and surgical measurements of the tricuspid annulus size: clinical implications. Circ Cardiovasc Imaging. 2015;8:e3241.CrossRefGoogle Scholar 14. Dreyfus GD, Corbi PJ, Chan KM, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair? Ann Thorac Surg. 2005;79:127–32.CrossRefGoogle Scholar 15. van de Veire NR, Braun J, Delgado V, et al. Tricuspid annuloplasty prevents right ventricular dilatation and progression of tricuspid regurgitation in patients with tricuspid annular dilatation undergoing mitral valve repair. J Thorac Cardiovasc Surg. 2011;141:1431–9.CrossRefGoogle Scholar 16. Lee H, Sung K, Kim WS, et al. Clinical and hemodynamic influences of prophylactic tricuspid annuloplasty in mechanical mitral valve replacement. J Thorac Cardiovasc Surg. 2016;151:788–95.CrossRefGoogle Scholar 17. Badhwar V, Rankin JS, He M, et al. Performing concomitant tricuspid valve repair at the time of mitral valve operations is not associated with increased operative mortality. Ann Thorac Surg. 2017;103:587–93.CrossRefGoogle Scholar 18. Navia JL, Brozzi NA, Klein AL, et al. Moderate tricuspid regurgitation with left-sided degenerative heart valve disease: to repair or not to repair? Ann Thorac Surg. 2012;93:59–67.CrossRefGoogle Scholar 19. Calafiore AM, Iaco AL, Romeo A, et al. Echocardiographic-based treatment of functional tricuspid regurgitation. J Thorac Cardiovasc Surg. 2011;142:308–13.CrossRefGoogle Scholar 20. Kim JB, Yoo DG, Kim GS, et al. Mild-to-moderate functional tricuspid regurgitation in patients undergoing valve replacement for rheumatic mitral disease: the influence of tricuspid valve repair on clinical and echocardiographic outcomes. Heart. 2012;98:24–30.CrossRefGoogle Scholar 21. Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013;14:611–44.CrossRefGoogle Scholar 22. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16:233–70.CrossRefGoogle Scholar 23. Shiran A, Sagie A. Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management. J Am Coll Cardiol. 2009;53:401–8.CrossRefGoogle Scholar 24. Song H, Kim MJ, Chung CH, et al. Factors associated with development of late significant tricuspid regurgitation after successful left-sided valve surgery. Heart. 2009;95:931–6.CrossRefGoogle Scholar 25. Kitai T, Furukawa Y, Murotani K, et al. Therapeutic strategy for functional tricuspid regurgitation in patients undergoing mitral valve repair for severe mitral regurgitation. Int J Cardiol. 2017;227:803–7.CrossRefGoogle Scholar 26. Chikwe J, Itagaki S, Anyanwu A, Adams DH. Impact of concomitant tricuspid annuloplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery hypertension after repair of mitral valve prolapse. J Am Coll Cardiol. 2015;65:1931–8.CrossRefGoogle Scholar 27. Matsunaga A, Duran CM. Progression of tricuspid regurgitation after repaired functional ischemic mitral regurgitation. Circulation. 2005;112:I453–I7.CrossRefGoogle Scholar 28. Di Mauro M, Bivona A, Iaco AL, et al. Mitral valve surgery for functional mitral regurgitation: prognostic role of tricuspid regurgitation. Eur J Cardiothorac Surg. 2009;35:635–9.CrossRefGoogle Scholar 29. Yilmaz O, Suri RM, Dearani JA, et al. Functional tricuspid regurgitation at the time of mitral valve repair for degenerative leaflet prolapse: the case for a selective approach. J Thorac Cardiovasc Surg. 2011;142:608–13.CrossRefGoogle Scholar 30. Fukuda S, Gillinov AM, Song JM, et al. Echocardiographic insights into atrial and ventricular mechanisms of functional tricuspid regurgitation. Am Heart J. 2006;152:1208–14.CrossRefGoogle Scholar 31. Calafiore AM, Gallina S, Iaco AL, et al. Mitral valve surgery for functional mitral regurgitation: should moderate-or-more tricuspid regurgitation be treated?A propensity score analysis. Ann Thorac Surg. 2009;87:698–703.CrossRefGoogle Scholar Copyright information © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. Authors and Affiliations R. Jansen1B. R. van Klarenbosch1M. J. Cramer1R. C. A. Meijer2P. H. M. Westendorp3H. W. J. Meijburg4J. J. J. Bucx5S. A. J. Chamuleau1Email authorJ. Kluin61.Department of CardiologyUniversity Medical Center UtrechtUtrechtThe Netherlands2.Department of Cardiothoracic SurgeryUniversity Medical Center UtrechtUtrechtThe Netherlands3.Department of CardiologyBeatrix Hospital GorinchemGorinchemThe Netherlands4.Department of CardiologyJeroen Bosch Hospital ’s-Hertogenbosch’s-HertogenboschThe Netherlands5.Department of CardiologyDiakonessenhuis UtrechtUtrechtThe Netherlands6.Department of Cardiothoracic SurgeryAcademic Medical Center AmsterdamAmsterdamThe Netherlands


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007%2Fs12471-018-1159-4.pdf

R. Jansen, B. R. van Klarenbosch, M. J. Cramer, R. C. A. Meijer, P. H. M. Westendorp, H. W. J. Meijburg, J. J. J. Bucx, S. A. J. Chamuleau, J. Kluin. Longitudinal echocardiographic and clinical follow-up of patients undergoing mitral valve surgery without concomitant tricuspid valve repair, Netherlands Heart Journal, 2018, 1-10, DOI: 10.1007/s12471-018-1159-4